Apremilast for treatment of recurrent erythema multiforme

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Recurrent erythema multiforme with oralinvolvement is therapeutically challenging.Apremilast has been used with success in resolvingthe oral aphthae of Behçet disease, prompting theuse of the drug in patients with oral erosions fromerythema multiforme. Three patients with oralerythema multiforme were given apremilast at dosesof 30-60mg daily. Complete clearance of the lesionswere observed in all three patients, including thoserefractory to other standard therapies. Apremilast maypresent an effective option for recurrent erythemamultiforme for patients who have failed trials antiviraland immunosuppressive therapies.

Original languageEnglish
JournalDermatology Online Journal
Issue number1
StatePublished - 15 Jan 2017


Dive into the research topics of 'Apremilast for treatment of recurrent erythema multiforme'. Together they form a unique fingerprint.

Cite this